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Abstract
Purpose: A review of the literature to identify modifiable influences on fe-
male human papillomavirus (HPV) vaccine uptake relevant to clinical practice
in order to support nurse practitioners (NPs) in the prevention of cervical can-
cer.
Data sources: PubMed, CINAHL, reference lists of publications that surfaced
in the electronic search.
Conclusions: Six influences are modifiable and potentially amenable to be-
ing addressed at the clinic encounter level: (a) cost and insurance coverage,
(b) provider recommendation, (c) vaccination opportunity, (d) HPV and HPV
vaccine knowledge, (e) vaccine safety concerns, and (f) HPV risk.
Implications for practice: NPs have an important role in improving HPV
vaccine uptake and research suggests several areas they can address to increase
vaccination during clinic visits.
Introduction
Infection with human papillomavirus (HPV) is the es-
tablished cause of most cervical cancers (Bosch, Lorincz,
Munoz, Meijer, & Shah, 2002) and costs the U.S. health
system 5 billion dollars a year in direct medical costs (In-
singa, Dasbach, & Elbasha, 2005). In the United States,
25% of 14- to 19-year-old females, 45% of 20- to 24-
year-old females, and 27% of 25- to 29-year-old females
are infected with HPV (Dunne et al., 2007). The Advi-
sory Committee on Immunization Practices (ACIP) rec-
ommends universal HPV vaccination for all females (since
2006) and males (since 2011) starting at age 11–12. Ac-
ceptability of the vaccine is high (55%–100%) among
adolescents, young adults, and parents of adolescents
(Brewer & Fazekas, 2007). However, only 49% of ado-
lescent females have initiated the series and only 32%
have received all three doses required for full immuniza-
tion (Centers for Disease Control and Prevention, 2011).
Even fewer young adult females have started the series,
with national estimates at 17% (Centers for Disease Con-
trol and Prevention, 2010).
Nurse practitioners (NPs) play a vital role in making
sure their patients receive cancer protection through vac-
cination, but may not have a clear understanding about
what areas they can address with patients to improve vac-
cination. This literature review was conducted to identify
modifiable influences on female HPV vaccine uptake rel-
evant to clinical practice in order to support NPs in the
prevention of cervical cancer.
Methods
An electronic search was conducted in PubMed using
the search term “hpv vaccine.” The search was limited to
humans and female participants, as routine recommen-
dation for HPV vaccination was limited to females un-
til October 2011, and the search was limited to publica-
tions in English, as the journals reporting results in the
United States are published in English. The search was
also limited to articles published between January 1, 2009
and June 1, 2011, the time period when researchers be-
gan publishing HPV vaccine uptake studies. CINAHL was
searched separately using the same search term and time
limitations to identify any additional studies not available
in PubMed. Hand searches were also performed of refer-
ence lists of publications that surfaced in the electronic
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search and met the inclusion criteria, and the first author
added her own publication.
Studies were included if they provided direct measure-
ment of uptake (not simply intention to vaccinate) and
used variables the investigator identified as modifiable in
clinical practice (such as costs, recommendations, oppor-
tunity, knowledge, and risk). Studies were excluded if
they examined variables unable to be modified directly in
clinical practice, such as race or ethnicity, age, education
level, income, marital status, or number of previous hos-
pitalizations. Studies were also excluded if they were not
conducted in the United States, in order to increase rel-
evance to clinical practice within the United States. Each
study was analyzed to identify the main findings. Similar
variables from the main findings were grouped together
to extract summary factors of modifiable influences at the
clinic encounter level.
Results
Of the 1074 articles identified through the electronic
database search, a total of 19 articles met the inclu-
sion criteria. Table S1 summarizes the findings from
these studies. Six modifiable influences relevant to clini-
cal practice were extracted from the studies (see Table 1).
The six influences were (a) cost and insurance coverage,
(b) provider recommendation, (c) vaccination opportu-
nity, (d) HPV and HPV vaccine knowledge, (e) vaccine
safety concerns, and (f) HPV risk (including documented
HPV risk factors or perceived HPV risk).
Cost and insurance coverage
Cost and insurance coverage is potentially modifiable
at the clinic encounter in that organizations may have
access to resources for patients who cannot afford to pay.
Cost and insurance coverage in general differs greatly be-
tween females younger than 19 years of age, who are
more often insured and may be eligible for free vac-
cines through the Vaccines for Children program, and fe-
males 19 and older who are less commonly insured and
have limited access to vaccine-specific funding. Of the
seven studies that addressed cost and insurance cover-
age as influences on HPV vaccination (Caskey, Lindau, &
Alexander, 2009; Conroy et al., 2009; Dempsey, Cohn,
Dalton, & Ruffin, 2009; Jain et al., 2009; Moore,
Crosby, Young, & Charnigo, 2010; Schluterman, Terplan,
Lydecker, & Tracy, 2011; Zimet, Weiss, Rosenthal, Good,
& Vichnin, 2010), most found cost and insurance cover-
age to be an influence in the young adult age group.
Across the eligible age range, in a longitudinal sur-
vey of 189 females 13- to 26-year-old, Conroy et al.
Table 1 HPV vaccine uptake studies by inﬂuence
Inﬂuence Study
Cost and insurance coverage Caskey et al. (2009)
Conroy et al. (2009)
Dempsey et al. (2010)
Jain et al. (2009)
Moore et al. (2010)
Schluterman et al. (2011)
Zimet et al. (2010)
Provider recommendation Caskey et al. (2009)
Conroy et al. (2009)
Dempsey et al. (2009)
Gerend et al. (2009)
Gottlieb et al. (2009)
Guerry et al. (2011)
Rosenthal et al. (2011)
Vaccination opportunity Caskey et al. (2009)
Chao et al. (2010)
Cook et al. (2010)
Dempsey et al. (2010)
Reiter et al. (2010)
Small and Patel (2012)
HPV and HPV vaccine knowledge Brewer et al. (2011)
Caskey et al. (2009)
Gerend et al. (2009)
Gottlieb et al. (2009)
Guerry et al. (2011)
Licht et al. (2010)
Mathur et al. (2010)
Zimet et al. (2010)
Vaccine safety concerns Dempsey et al. (2009)
Gerend et al. (2009)
Zimet et al. (2010)
HPV risk Caskey et al. (2009)
Chao et al. (2010)
Cook et al. (2010)
Dempsey et al. (2009)
Gottlieb et al. (2009)
Licht et al. (2010)
Moore et al. (2010)
Zimet et al. (2010)
Note. HPV, human papillomavirus.
(2009) identified insurance coverage for the vaccine as
the strongest predictor of HPV vaccine initiation (odds
ratio [OR] 5.31, 95% confidence interval [CI] 1.61–
17.49). Demonstrating the difference between the two
age groups, 27% of 18- to 26-year-old females cited cost
as a reason for foregoing vaccination, while only 10% of
younger females ages 13–17 years cited cost as a barrier
(n = 1011; Caskey et al., 2009).
Among studies specific to young adults, who are there-
fore no longer eligible for the Vaccines for Children pro-
gram, in an analysis of the 2007 National Immunization
Survey-Adult data, Jain et al. (2009) found having health
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insurance as one of the only variables associated with ini-
tiation (p < .05, n = 168). In another study of 19- to
26-year-old insured females, 24.4% cited uncertainty
about insurance coverage as a reason for not vaccinating
(n = 185; Zimet et al., 2010).
Even the type of insurance seems to have an ef-
fect on vaccination. In a study of outpatient gyneco-
logic clinics, 47% of the 9- to 26-year-old females who
initiated the HPV vaccine series had public insurance
compared to 28% with private insurance (p < .01, n =
8069; Schluterman et al., 2011). This finding was repli-
cated in young adults specifically, where having public
insurance increased the likelihood of vaccination initia-
tion when compared to private insurance (OR 0.52, 95%
CI 0.45–0.59) or no insurance (OR 0.47, 95% CI 0.26–
0.85, n = 10,082; Dempsey et al., 2010). However, the
reverse was true when assessing vaccine series comple-
tion, with privately insured individuals more likely than
publicly insured individuals to complete all three doses.
One study evaluated the impact of eliminating cost as a
barrier by providing a free vaccine voucher at a university
health center. This was the only study that provided an
intervention to evaluate the effect of cost as an influence.
As a result, 50% of the participants (n = 209) utilized the
voucher to initiate vaccination (Moore et al., 2010).
Provider recommendation
Perhaps the most clinically relevant factor that has
repeatedly been shown to influence HPV vaccine up-
take is provider recommendation. Seven studies con-
firmed that discussing the vaccine and receiving a rec-
ommendation from a healthcare provider often results
in receipt of the vaccine (Caskey et al., 2009; Conroy
et al., 2009; Dempsey, Abraham, Dalton, & Ruffin, 2009;
Gerend, Weibley, & Bland, 2009; Gottlieb et al., 2009;
Guerry et al., 2011; Rosenthal et al., 2011). One survey of
19- to 26-year-old females, in which all participants were
insured, found even the strength of the physician rec-
ommendation mattered, with patients who perceived a
stronger recommendation from their physician having a
four times greater likelihood of vaccinating than those
who perceived a weaker recommendation from their
physician (n = 530; Rosenthal et al., 2011).
While less modifiable but still important to understand,
the specialty of the provider may be influential. One
study of Kaiser Permanente’s immunization data found
that having a pediatrician as a primary care provider was
correlated with vaccine initiation when compared to fam-
ily medicine providers (RR 0.81, 95% CI 0.79–0.83) or
internal medicine providers (RR 0.93, 95% CI 0.87–1.00,
n = 285,265; Chao, Velicer, Slezak, & Jacobsen, 2010).
A larger study of clinic visit data confirmed the influence
of provider specialty where pediatric providers were posi-
tively correlated with HPV vaccination when compared to
family medicine (OR 0.92, 95% CI 0.81–1.04) or gynecol-
ogy providers (OR 0.24, 95% CI 0.18–0.33, n = 10,082;
Dempsey et al., 2010). These findings are consistent with
uptake among other vaccines, not just the HPV vaccine,
showing pediatricians consistently outperforming other
provider specialties in vaccine administration.
Provider characteristics other than specialty may also
influence vaccine uptake. Having a male primary care
provider was inversely associated with vaccine initia-
tion (RR 0.92, 95% CI 0.91–0.93, n = 285,265) when
compared to female primary care providers (Chao et al.,
2010). Also, one of the first studies to explore influences
on mothers’ decisions to vaccinate daughters found that
mothers who declined vaccination at a healthcare visit
had more often seen someone other than their usual
healthcare provider (n = 52). This supports the belief that
the strength of the relationship between provider and pa-
tient also matters, and not just the provider specialty or
gender (Dempsey et al., 2009).
Vaccination opportunity
Four studies found that females with a recent health-
care visit were more likely to have received the HPV vac-
cine than those without a recent healthcare visit (Caskey
et al., 2009; Chao et al., 2010; Dempsey et al., 2010; Re-
iter et al., 2010), as the healthcare visit serves as an op-
portunity to access the vaccine. A total of 13% of parents
interviewed in North Carolina cited the lack of a health-
care visit as the reason they had not initiated vaccination
for their daughters (n = 889; Gottlieb et al., 2009). How-
ever, the frequency of healthcare visits did not seem to be
associated with vaccination (n = 177; Mathur, Mathur,
& Reichling, 2010). Females who attended an outpatient
visit (n = 718,660; Cook et al., 2010) and females who at-
tended a preventive maintenance visit (OR 5.18, 95% CI
4.64–5.79, n = 10,082; Dempsey et al., 2010) were more
likely to initiate HPV vaccination than those attending a
problem-focused visit. This finding supports the under-
standing that vaccination opportunity specifically, rather
than healthcare visits generally, influence vaccination, as
preventive maintenance visits are traditionally when vac-
cination status is addressed.
One study showed that having the vaccine available at
a clinic visit makes a difference. Four years after the vac-
cine became available to the public, vaccine availability
at a clinic visit increased vaccination from 11.1% prior to
health center availability to 17.0% after it became avail-
able at the health center (n = 171; Small & Patel, 2012).
521
Modiﬁable inﬂuences on female HPV vaccine uptake S. L. Small et al.
HPV and HPV vaccine knowledge
Knowledge about HPV and HPV vaccines are often
modifiable at the clinic encounter as health centers have
the opportunity to educate patients and parents about
the common virus and vaccine protection available. Eight
studies examined HPV and HPV vaccine knowledge, as
well as the source of that knowledge, as an influence
on vaccination (Brewer et al., 2011; Caskey et al., 2009;
Gerend et al., 2009; Gottlieb et al., 2009; Guerry et al.,
2011; Licht et al., 2010; Mathur et al., 2010; Zimet
et al., 2010). The results were mixed of how impor-
tant these influences are on vaccine uptake, although
knowledge never dissuaded vaccination. Differences may
vary among parents of adolescents, whose are deciding
whether or not to vaccinate their child, and young adults,
who are often deciding to vaccinate themselves.
Among studies of parents of adolescents, knowledge
of the HPV vaccine (but not HPV) was correlated with
uptake in a small (n = 82) study of parents (t −3.214,
p < .01; Gerend et al., 2009). In an early survey of par-
ents, 14% had not heard of the vaccine (13% had not
seen a healthcare provider) and the most commonly cited
(22%) reason for not initiating was the need for more
information (n = 889; Gottlieb et al., 2009). This study
was conducted only a year after the HPV vaccine was
approved and only 10% of those surveyed had initiated
vaccination. Two later studies supported the finding that
needing more information about the HPV vaccine de-
creased the likelihood of vaccine initiation (adjusted odds
ratio [aOR] 0.08, 95% CI 0.04–0.2, n = 509; Guerry et al.,
2011) and not needing more information increased the
likelihood of initiation (adjusted risk ratio [aRR] 0.41,
95% CI 0.22–0.76, n = 650; Brewer et al., 2011).
Among young adults, in a study of 406 university fe-
males, participants who knew that HPV caused genital
warts were more likely to be vaccinated (aOR 1.85, 95%
CI 1.20–2.93, n = 406; Licht et al., 2010). Two years after
vaccine availability, 31.7% (n = 185) of females reported
lack of information about the vaccine as a reason for not
initiating vaccination (Zimet et al., 2010).
The source of vaccine information may also influence
vaccine uptake across the eligible age range. A large,
nationally representative survey (n = 1011) found that
vaccinated females were more likely to identify health-
care providers as their source of HPV vaccine informa-
tion (69%) than unvaccinated females (28%), and 77%
of all participants identified their healthcare provider as
the source of HPV information they trust most (Caskey
et al., 2009). This study did not differentiate types of
healthcare providers. One survey of 177 high school fe-
males in California asked about the source of HPV vac-
cine knowledge and found that learning about the HPV
vaccine from a physician or nurse was associated with
vaccination (Mathur et al., 2010).
Vaccine safety concerns
Three studies indicated that vaccine safety concerns in-
fluence vaccine uptake (Dempsey et al., 2009; Gerend
et al., 2009; Zimet et al., 2010). A study interviewing
mothers of 11- to 17-year-old females who attended a
recent healthcare visit found 8 of the 19 mothers of un-
vaccinated daughters cited safety concerns because of its
recent availability as a reason for declining vaccination
(Dempsey et al., 2009). Even in mothers who chose to
vaccinate, 7 of 33 expressed concerns about safety, but
felt the benefits outweighed the risks (Dempsey et al.,
2009). In 19- to 26-year-old females less than 2 years af-
ter vaccine approval, participants reported the newness
of the vaccine (35.4%) and side effect concerns (24.4%)
as reasons for not initiating vaccination (n = 185; Zimet
et al., 2010). In a survey also approximately 2 years after
HPV vaccine availability, 24% of parents (n = 82) indi-
cated the vaccine would have to be on the market for
more than 5 years before they would feel comfortable
providing it for their daughter (Gerend et al., 2009).
HPV risk
Eight studies examined HPV risk as an influence on
HPV vaccination, either through documented risk factors
or risk perception (Caskey et al., 2009; Chao et al., 2010;
Cook et al., 2010; Dempsey et al., 2009; Gottlieb et al.,
2009; Licht et al., 2010; Moore et al., 2010; Zimet et al.,
2010). Two studies examined clinical risk factors for HPV.
Chao et al. (2010) found in 18- to 26-year-old females
that risk factors for HPV, including history of sexually
transmitted infections, abnormal Pap smears, and oral
and transdermal contraceptive use are associated with
HPV vaccine uptake (n = 285,265). This study examined
a mostly insured population and did not investigate why
the association exists. Conversely, a study of university
females found that sexual activity in the past 12 months,
a history of a Pap smear or abnormal Pap smear, or a his-
tory of a sexually transmitted infection was not associated
with vaccination (n = 209; Moore et al., 2010).
Six of the studies examined HPV risk perception. Moth-
ers (n = 52) who declined vaccination for their daughters
cited low HPV risk as a contributing factor in their de-
cision, and those who chose vaccination protection for
their daughters recognized high risk of HPV as motivating
their choice (Dempsey et al., 2009). In a larger study (n
= 889), 12.6% of parents with unvaccinated daughters
cited the belief that their daughter was not yet sexually
active as a reason for not initiating the vaccine (Gottlieb
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Table 2 Implications for practice
Inﬂuence Recommendation
Cost and insurance coverage For clinicians of patients under age 19, providers should enroll in the Vaccines for Children program,
enabling patients who are Medicaid eligible, uninsured, underinsured, American Indian or Alaska Native
to receive free vaccine (www.cdc.gov/vaccines/programs/vfc/). Patients 19 and older without health
insurance coverage who meet certain income guidelines may qualify for free vaccines through the Merck
Vaccine Patient Assistance Program (www.merck.com/merckhelps).
Provider recommendation All clinicians should recognize their own inﬂuence on patients’ decisions to vaccinate, regardless of
specialty, and responsibly convey vaccine recommendations consistent with evidence-based guidelines.
Vaccination opportunity Clinicians should supply the HPV vaccine, recognizing that any visit may be their patients’ only opportunity.
HPV and HPV vaccine knowledge Clinicians should provide accurate, evidence-based information about HPV and the HPV vaccine to all
patients eligible for vaccination.
Vaccine safety concerns Should safety concerns arise, clinicians can reassure patients that ongoing postlicensure safety surveillance
and 23 million doses distributed continue to conﬁrm very high vaccine safety (Slade et al., 2009).
HPV risk Clinicians should reinforce the message that the HPV vaccine is indicated as a routine immunization, not risk
based.
et al., 2009). Thirty percent of 13- to 26-year-old females
also reported their lack of sexual activity as a reason for
not vaccinating (n = 1011; Caskey et al., 2009). A study
of Florida Medicaid patients (n = 718,660) found sexual
activity to be positively associated with vaccine initiation
(OR 1.19, 95% CI 1.15–1.24; Cook et al., 2010). How-
ever, another study of university females found that risk
perception (Licht et al., 2010) had no association with
vaccination (n = 406). In a study of 19- to 26-year-old
females (n = 185), the most commonly cited reason for
not initiating vaccination was the belief that they were in
a monogamous relationship (Zimet et al., 2010).
Discussion
Because of the relatively recent availability of HPV vac-
cines, research is still in the early stages of evaluating up-
take. However, a review of 19 available studies explor-
ing HPV vaccine uptake did reveal six potentially mod-
ifiable influences amenable to being addressed at the
clinic encounter level: (a) cost and insurance coverage,
(b) provider recommendation, (c) vaccination opportu-
nity, (d) HPV and HPV vaccine knowledge, (e) vaccine
safety concerns, and (f) HPV risk. See Table 2 for practice
implications of these modifiable influences.
Research on HPV vaccine uptake began to take place
soon after vaccine approval in 2006 and began to ap-
pear in publications in 2009. The studies reported a wide
range of vaccine initiation, from 9% to 65%, which
may affect specific findings, but clearly demonstrates that
high vaccination rates are possible. Research examin-
ing what is working in those areas with 65% uptake is
needed, and also what is preventing vaccination in those
areas with 9% vaccination rates. However, it should
be noted that no study has demonstrated uptake levels
in the United States that meet the 80% national tar-
get immunization level set forth in Healthy People 2020
(www.healthypeople.gov).
Much of the research has focused on adolescents as pa-
tients and their parents as providers of consent, as vac-
cine initiation is recommended at age 11–12 years old.
However, catch-up vaccination is recommended by the
ACIP for all females through age 26 (Centers for Dis-
ease Control and Prevention, 2007), which encompasses
a young adult group that will still benefit from the vaccine
but may experience very different influences when fac-
ing vaccination. As adolescents transition into adulthood,
they begin to make healthcare decisions without parental
consent and often face fragmented healthcare delivery
systems as they transit from pediatric providers to family,
internal medicine, or reproductive health providers, and
attend fewer preventive care visits (Rand et al., 2007).
Further research is needed that focuses on the differences
between the adolescent and young adult populations.
In addition, much of the clinical research has studied
patients who are mostly insured, or are uninsured but
under the age of 19 and therefore eligible for the Vac-
cines for Children program. Vaccines for Children is a
federally funded, state-administered program that pays
for many of the vaccines given to children in the United
States. Young adults are not eligible for the Vaccines for
Children program, leaving them with fewer cost cover-
age options for one of the most expensive vaccines on the
market. The 19- to 26-year-old age group may face un-
stable insurance coverage as they move through school,
unemployment, or the initial years of adult employment.
Further research is needed that focuses on the uninsured
population and ways to remove cost barriers.
The findings describing the association of provider char-
acteristics with HPV vaccine initiation are limited in that
they cannot explain if pediatric providers themselves, for
example, are more likely to discuss, recommend, and
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carry vaccines, as is the case with other vaccines, or if
relationships with pediatric providers have been more
longstanding by adolescence, thereby increasing trust and
influence, or even perhaps if those patients seeing pedi-
atric providers are more amenable to vaccination.
Finally, because of the rapid changes occurring since
the introduction of the HPV vaccine in 2006, the
existing research may already be considered outdated.
Initial research at the time of vaccine availability demon-
strated high acceptability of the vaccine across a vari-
ety of populations (Brewer & Fazekas, 2007), which has
not translated into high vaccine uptake, preventing re-
searchers from relying on acceptability research to de-
velop predictors of HPV vaccine uptake. Since then, even
intention to vaccinate has not been shown to be a reliable
predictor of HPV vaccine uptake, with one study show-
ing only 38% of parents who intended on vaccinating
their daughter having done so a year later (Brewer et al.,
2011). As a result, researchers will have to continue to
study influences and predictors specific to uptake, with-
out relying on acceptability or intention.
Since its approval, the vaccination process is rapidly
progressing from its initial stages of availability to a time
when the healthcare system has had the opportunity to
become knowledgeable about the vaccine, establish sys-
tems and mechanisms for its delivery, and incorporate it
into routine care. Nevertheless, we know that HPV vac-
cine uptake remains far below the Healthy People 2020
goal of 80% (www.healthypeople.gov), so much work
remains for NPs.
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